Comparing the Prognosis of Patients With Cardia and Non-cardia Gastric Cancer.

Comparing the Stage-for-Stage Prognosis of Patients With Cardia and Non-cardia Gastric Cancer After Operation.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03895008

Enrollment

1000

Registered

2019-03-29

Start date

2019-07-08

Completion date

2024-12-31

Last updated

2019-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

Cardia gastric cancer, Non-cardia gastric cancer, Resection, Prognosis

Brief summary

To comparing the stage-for-stage prognosis of patients with cardia and non-cardia gastric cancer after operation.

Detailed description

The aim of this study is to compare the stage-for-stage prognosis of patients with cardia and non-cardia gastric cancer after operation.In this study, patients with cardiac and non-cardiac gastric cancer who undergo radical resection from January 2019 to December 2024 will be included. We will follow up the patient's progression, recurrence time and survival time.

Interventions

OTHERCardia and Non-cardia gastric cancer

We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Histopathology or cytopathology proven cardia or non-cardia gastric cancer; 2. Operable gastric cancer patients: primary lesions can be completely excision, no distant metastasis; 3. Life expectancy of at least 6 months; 4. ECOG（Eastern Cooperative Oncology Group ） score 0-1; 5. Age: 18\ 80 years old; 6. Normal hemodynamic indices before the recruitment (including blood cell count and liver/kidney function). For example: WBC（White blood cell count ）\>4.0×109/L; NEU（Neutrophils）\>1.5×109/L; PLT（Platelet）\>100×109/L; 7. Roughly normal cardiopulmonary function: No coronary heart disease, myocardial infarction, pulmonary heart disease, refractory hypertension; 8. Not concomitant with other uncontrollable benign diseases before the recruitment; 9. Voluntarily signed the informed consent.

Exclusion criteria

1. Advanced gastric cancer patients with distant metastasis and inoperable ; 2. Pregnant or lactating women; 3. Patients who have no desire to participate in the study.

Design outcomes

Primary

Measure	Time frame	Description
Disease Free Survival（DFS）	5 years	The time from the primary operation to disease recurrence or death.

Secondary

Measure	Time frame	Description
Overall survival(OS)	5 years	OS is defined as the time from the end of radical surgery to death for any reason or at the last follow-up.

Countries

China

Contacts

Primary ContactJiuda Zhao, M.D.

jiudazhao@126.com+869716162732

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026